(P087) Proton Therapy Results in Low Rates of Acute GI Toxicity for Parotid Cancers

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Proton therapy for parotid cancers results in very low rates of GI toxicity. Nutritional status and weight were preserved throughout therapy. These results should be validated with patient-reported outcomes.

Roi Dagan, MD, MS, Curtis Bryant, MD, MPH, Christopher G. Morris, MS, Daniel J. Indelicato, Julie A. Bradley, MD, William M. Mendenhall, MD; University of Florida

BACKGROUND: Acute gastrointestinal (GI) toxicity from head-and-neck radiotherapy (RT) results in decreased quality of life. Increasingly, conformal RT has improved toxicity outcomes. The target for parotid tumors is ideal for proton therapy, because distal to the Bragg peak, there is no exit of radiation to the oral cavity, swallowing musculature, or contralateral major salivary glands.

PURPOSE: To evaluate acute GI toxicity from proton therapy for parotid cancers.

METHODS: A total of 23 patients were treated with primary (n =7) or adjuvant (n = 16) proton therapy for cancers of the parotid region, including salivary gland carcinoma (n = 16), skin carcinoma with perineural invasion (n = 5), and Ewing sarcoma (n = 1). The most common indication for proton therapy was skull base invasion. Double-scattered conformal proton therapy, typically involving three fields, was delivered to a median dose of 70 Gy (relative biological effectiveness [RBE]) (range: 55,8–74.4 Gy[RBE]) using various fractionations (range: 1.8–2 Gy[RBE]) once daily, 5 fractions/week (n = 15); 1.2 Gy(RBE) twice daily, 10 fractions/week (n = 7); and 2 Gy(RBE) once daily, 6 fractions/week (n = 1). Seven patients received concurrent chemotherapy. Acute toxicities were prospectively evaluated weekly during radiotherapy using Common Terminology Criteria for Adverse Events version 3 (CTCAE v3).

RESULTS: Grade (G) 3 dysphagia occurred during 1 week of therapy in one patient with baseline G2 dysphagia before RT after undergoing parotidectomy, mandible resection, and full-mouth extractions. A percutaneous gastrostomy tube was placed before RT and removed upon completing RT when dysphagia improved to G1. There were no other G3 events. G0, 1, 2, and 3 dysphagia rates were 87%, 4%, 9%, and 0% at baseline and 48%, 26%, 26%, and 0% at the end of RT, respectively. Among patients without G2 dysphagia at baseline, there was no difference between the rates of G0/1 and G2+ dysphagia at the end of RT compared with baseline (P = .104). Similar results were noted for xerostomia, dysgeusia, and weight loss. G2 mucositis occurred in 35% of patients-a significant change from baseline (P = .046)-but 43% of patients had no mucositis upon completing RT. The median weight at the end of RT was 97.4% of baseline. Only six patients (23%) lost > 5% of their baseline weight, and one patient (4%) lost > 10%.

CONCLUSIONS: Proton therapy for parotid cancers results in very low rates of GI toxicity. Nutritional status and weight were preserved throughout therapy. These results should be validated with patient-reported outcomes. 

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Related Content